1. Slide Source: Lipids Online Slide Library www.lipidsonline.org Women’s Health Initiative: Trial of Estrogen plus Progestin 16,608 women randomized 16,608 women randomized Conjugated equine estrogens 0.625 mg/d + medroxyprogesterone acetate 2.5 mg/d vs. placebo Conjugated equine estrogens 0.625 mg/d + medroxyprogesterone acetate 2.5 mg/d vs. placebo Primary outcome: nonfatal MI or CHD death Primary outcome: nonfatal MI or CHD death Primary adverse outcome: breast cancer Primary adverse outcome: breast cancer Stopped early (mean follow-up 5.2 years) because health risks exceeded benefits Stopped early (mean follow-up 5.2 years) because health risks exceeded benefits Writing Group for the WHI Investigators. JAMA 2002;288:321-333.

2. Slide Source: Lipids Online Slide Library www.lipidsonline.org *1st event: CHD; stroke; pulmonary embolism; breast, endometrial, or colorectal cancer; hip fracture, or death due to other causes Risks and Benefits of Estrogen/Progestin on Clinical Outcomes: Women’s Health Initiative Outcome Hazard Ratio Nominal 95% CI Adjusted 95% CI CHD (MI, coronary death) 1.291.02–1.630.85–1.97 CABG/PTCA1.040.84–1.280.71–1.51 Stroke1.41 1.07–1.85 0.86–2.31 Venous thromboembolic disease 2.11 1.58–2.82 1.26–3.55 Total CVD 1.221.09–1.361.00–1.49 Cancer1.030.90–1.170.86–1.22 Fractures0.760.69–0.850.63–0.92 Death0.980.82–1.180.70–1.37 Global index* 1.15 1.03 – 1.28 0.95 – 1.39 Writing Group for the WHI Investigators. JAMA 2002;288:321-333.

3. Slide Source: Lipids Online Slide Library www.lipidsonline.org Absolute Excess Risks and Absolute Risk Reductions per 10,000 Person-Years: Women’s Health Initiative Difference in risk per 10,000 person-years CHD events+7 Strokes+8 Pulmonary embolisms+8 Invasive breast cancer+8 Colorectal cancers–6 Hip fractures–5–5 Global index+19 Writing Group for the WHI Investigators. JAMA 2002;288:321-333.